Emerging drugs for high-grade osteosarcoma

Claudia Maria Hattinger, Michela Pasello, Stefano Ferrari, Piero Picci, Massimo Serra

Research output: Contribution to journalArticlepeer-review


Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5-10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.

Original languageEnglish
Pages (from-to)615-634
Number of pages20
JournalExpert Opinion on Emerging Drugs
Issue number4
Publication statusPublished - Dec 2010


  • drug resistance
  • osteosarcoma
  • tailored therapy
  • target-specific drugs
  • therapeutic markers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Emerging drugs for high-grade osteosarcoma'. Together they form a unique fingerprint.

Cite this